Share this article on:

ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II: Erratum

American Journal of Clinical Oncology: February 2017 - Volume 40 - Issue 1 - p 108
doi: 10.1097/COC.0000000000000368
Erratum

In the article that appeared on page 535 of the December 2016 issue, several author affiliations and a financial disclosure were incorrect in the article footnotes. The correct article footnotes are as follows:

“From the *University of Rochester Medical Center, Rochester, NY; †††Memorial Sloan Kettering Cancer Center, New York, NY, American Society of Clinical Oncology; †Stanford Cancer Center, Stanford, California, American Society of Clinical Oncology; ‡University of Southern California Keck School of Medicine, Los Angeles, CA; §University of Texas MD Anderson Cancer Center, Houston; ¶University of Texas Health Science Center at San Antonio, San Antonio, TX; ∥Emory University, Atlanta, GA, American Society of Clinical Oncology; #University of Florida Proton Therapy Institute, Jacksonville, FL; **University of Florida, Gainesville, FL; ††St. Jude Children’s Research Hospital, Memphis, TN, American Society of Clinical Oncology; ‡‡University of Pennsylvania Health System, Philadelphia, PA; §§Yale University School of Medicine, New Haven, CT; ∥∥Richard L. Roudebush VA Medical Center, Indiana University School of Medicine, Indianapolis, IN; ¶¶The University of Chicago, Chicago, IL, American Society of Hematology; ##Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, MD; and ***Massachusetts General Hospital, Boston, MA.

The American College of Radiology seeks and encourages collaboration with other organizations on the development of the ACR Appropriateness Criteria through society representation on expert panels. Participation by representatives from collaborating societies on the expert panel does not necessarily imply individual or society endorsement of the final document.

This article is a revised version of the American College of Radiology Appropriateness Criteria Hodgkin Lymphoma Favorable Prognosis Stage I and II, excerpts of which are reprinted here with permission. Practitioners are encouraged to refer to the complete version at http://www.acr.org/ac.

A.Y.: “Research Support: Novartis, J & J, Curis Honorarium: Bayer, BMS, Cegene, Incyte, Janssen, Sanofi, Seattle Genetics, Takeda Millenium.” C.R.F.: Optum RX—consultant. The other authors declare no conflicts of interest.

Reprint requests to: publications@acr.org.

Corresponding Author: Sughosh Dhakal, MD, American College of Radiology, 1891 Preston White Drive, Reston, VA 20191. E-mail: sughosh_dhakal@urmc.rochester.edu.

Copyright © 2016 American College of Radiology (ACR).

ISSN: 0277-3732/16/3906-0535

DOI: 10.1097/COC.0000000000000331”

Back to Top | Article Outline

REFERENCE

Dhakal S, Advani R, Ballas LK, et al. Expert Panel on Radiation Oncology–Lymphoma. ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II. Am J Clin Oncol. 2016;39:535–544.
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.